SCHEMBL23619600

SCHEMBL23619600

COc1ccc(CNc2nc(Cl)cc(N)c2N)c(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 12/20 0.50
CYP3A4 P08684 12/20 0.50
CYP2D6 P10635 12/20 0.50
CYP2C19 P33261 12/20 0.50
TSHR P16473 11/20 0.50
CYP2C9 P11712 6/20 0.50
ALDH1A1 P00352 5/20 0.50
HSD17B10 Q99714 4/20 0.50
HIF1A Q16665 2/20 0.50
APLNR P35414 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
DHFR P00374 1/20 0.49
LMNA P02545 4/20 0.47
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CLK4 Q9HAZ1 5/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
ALOX15 P16050 2/20 0.47
USP2 O75604 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22301803 0.85 DHFR (0.47) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL873390 0.83 DHFR (0.55) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL23852696 0.80 APLNR (0.59) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL31309621 0.80 PDE4B (0.44) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL30443473 0.80 CYP1A2 (0.54) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL25466388 0.80 CYP1A2 (0.54) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL17105218 0.78 CYP1A2 (0.55) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL22307619 0.78 CYP1A2 (0.58) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL27875036 0.78 APLNR (0.52) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL27376118 0.78 KDM4C (0.53) CYP1A2CYP3A4CYP2D6CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022147092-A1 COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES INCYTE CORPORATION (US) 2022-07-07 WO disclosed
WO-2021138512-A1 COMBINATION THERAPY COMPRISING A2A/A2B AND PD-1/PD-L1 INHIBITORS INCYTE CORPORATION (US) 2021-07-08 WO disclosed